Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 20/20 | 0.69 |
| ▸ | MTOR | P42345 | 9/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.65 |
| ▸ | ATR | Q13535 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18843686 | 1.00 | ATM (0.69) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL18843766 | 0.96 | ATM (0.66) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL18843821 | 0.96 | ATM (0.66) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL18824591 | 0.96 | ATM (0.66) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL18843767 | 0.96 | ATM (0.66) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL18824760 | 0.89 | ATM (0.67) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL18843780 | 0.89 | ATM (0.67) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL18843823 | 0.88 | ATM (0.68) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL18843825 | 0.88 | ATM (0.68) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL18843777 | 0.86 | ATM (0.73) | ATMMTORPIK3CAKCNH2ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180280377-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-10-04 | — | — | US | claimed |
| EP-3370722-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2018-09-12 | — | — | EP | claimed |
| WO-2017076898-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-05-11 | — | — | WO | claimed |
| US-20230256110-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-08-17 | — | — | US | disclosed |
| CN-116194109-A | Combination of antibody-drug conjugate and ATM inhibitor | 阿斯利康(英国)有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-4171651-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | AstraZeneca UK Limited (GB) | 2023-05-03 | — | — | EP | disclosed |
| WO-2021260580-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| US-20180280377-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| WO-2017076898-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256110-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | ATM, CHEK2, ERBB2 | ATM 1/4885MTOR 506/4885PIK3CA 1071/4885 |
| US-20180280377-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | ATM 1/4885MTOR 1304/4885PIK3CA 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.